Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 131.87
Bid (Size) 131.90 (49)
Ask (Size) 131.92 (100)
Prev. Close 131.87
Today's Range 131.87 - 131.87
52wk Range 80.83 - 131.95
Shares Outstanding 94,324,313
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Mark Minervini may look into INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) ↗
A fundamental and technical analysis of (NASDAQ:ITCI): Why INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) qualifies as a high growth stock. 
Via Chartmill

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+57.9%
+57.9%

More News

Read More
News headline image
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews ↗
Via Benzinga
News headline image
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended ↗
Via Benzinga
News headline image
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
Via Benzinga
News headline image
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews ↗
Via Benzinga
News headline image
Evaluating INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) using Mark Minervini’s winning stock formula ↗
Via Chartmill
News headline image
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy' ↗
Via Benzinga
News headline image
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday ↗
Via Benzinga
News headline image
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
Via Benzinga
News headline image
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗
Via Benzinga
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook ↗
Via Benzinga
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, HEES, SSTK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Top 4 Health Care Stocks You May Want To Dump In Q1 ↗
Via Benzinga
News headline image
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗
Via Benzinga
News headline image
MarketBeat Week in Review – 01/13 - 01/17
Via MarketBeat
Topics Economy Energy
News headline image
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗
Via Investor's Business Daily
Topics Economy
News headline image
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Via MarketBeat
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire

Frequently Asked Questions

Is Intra-Cellular Therapies Inc. - Common Stock publicly traded?
Yes, Intra-Cellular Therapies Inc. - Common Stock is publicly traded.
What exchange does Intra-Cellular Therapies Inc. - Common Stock trade on?
Intra-Cellular Therapies Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Intra-Cellular Therapies Inc. - Common Stock?
The ticker symbol for Intra-Cellular Therapies Inc. - Common Stock is ITCI on the Nasdaq Stock Market
What is the current price of Intra-Cellular Therapies Inc. - Common Stock?
The current price of Intra-Cellular Therapies Inc. - Common Stock is 131.87
When was Intra-Cellular Therapies Inc. - Common Stock last traded?
The last trade of Intra-Cellular Therapies Inc. - Common Stock was at 04/01/25 04:00 PM ET
What is the market capitalization of Intra-Cellular Therapies Inc. - Common Stock?
The market capitalization of Intra-Cellular Therapies Inc. - Common Stock is 12.44B
How many shares of Intra-Cellular Therapies Inc. - Common Stock are outstanding?
Intra-Cellular Therapies Inc. - Common Stock has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.